

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease

NCT05854641

Status	RECRUITING
Phase	Phase 4
Sponsor	Cell Bioputics Resources Sdn Bhd
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (6)

- Patients between 18-65 years old
- Patients diagnosed with atherosclerotic peripheral arterial disease
- Patients not eligible for or have failed surgical or percutaneous revascularization (No option patients)
- Patients with at least one ulcer (between 0.5 to 10 cm² size)
- Ankle brachial pressure index (ABPI) \geq 0.6 (toe brachial index (TBI) if ABPI out of range; TBI \geq 0.5)
- ... and 1 more (see full listing online)

Exclusion (4)

- Patients diagnosed with Buerger's disease by Shionoya criteria
- Patients eligible for surgical or percutaneous revascularization
- Patients with a history of participating in another stem cell trial or therapy within 3 months
- Patients who are unsuitable to participate the clinical trial as determined by investigators

Locations (1 total)

Hospital Canselor Tunku Mukhriz, Kuala Lumpur, Malaysia